Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adial Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ADIL
Nasdaq
8731
https://www.adialpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adial Pharmaceuticals Inc
Is Masimo (MASI) Outperforming Other Medical Stocks This Year?
- Mar 11th, 2024 1:40 pm
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
- Mar 2nd, 2024 12:00 am
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Lead Product For Alcohol Use Disorder
- Feb 28th, 2024 4:15 pm
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
- Feb 28th, 2024 2:30 pm
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
- Feb 15th, 2024 2:00 pm
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
- Feb 13th, 2024 2:15 pm
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
- Jan 18th, 2024 1:30 pm
Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate
- Dec 20th, 2023 2:00 pm
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement
- Nov 29th, 2023 9:05 pm
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 14th, 2023 10:02 pm
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference
- Oct 31st, 2023 12:30 pm
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy
- Oct 30th, 2023 4:00 pm
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar
- Oct 25th, 2023 12:00 pm
Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Oct 24th, 2023 8:30 pm
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Oct 20th, 2023 12:00 pm
EXCLUSIVE: Adial Pharma Announces Key Patent To Combine Genetic Diagnostic With Lead Drug For Alcohol Addiction
- Oct 19th, 2023 4:00 pm
Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th
- Oct 19th, 2023 4:00 pm
Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence
- Oct 19th, 2023 2:30 pm
Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award
- Oct 18th, 2023 12:00 pm
Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder
- Sep 28th, 2023 11:00 am
Scroll